The NCCN Category 1 designation for Signatera — Natera's circulating tumor DNA (ctDNA) test — represents the highest level of clinical consensus endorsement, signaling uniform agreement among NCCN panelists based on high-level evidence. For a liquid biopsy test, this is a critical unlock: payers routinely tie coverage and reimbursement decisions to NCCN guidelines, meaning the designation directly widens Signatera's billable patient base and reduces prior-authorization friction across major oncology indications.

Natera enters this catalyst with 35.9% YoY revenue growth but still running a -9.0% net margin and -$1.52 diluted EPS, so the bull case rests entirely on the revenue ramp trajectory rather than current profitability. The key watch items are: how quickly CMS and commercial payers update coverage policies to reflect the new NCCN status, whether Natera raises FY guidance at the next earnings print, and whether the stock — which has historically been sensitive to reimbursement catalysts — sustains a breakout above prior resistance levels.